Xencor Inc (XNCR) stock
Close on Nov 17, 2026Market cap $2.57BP/E –Yield –
Xencor Inc saw revenue fall 28.6% to $104.97M over the twelve months to Jun 30, 2026. Free cash flow was -$208.29M. At the latest close the market valued the company at $2.57B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.57B
- P/E ratio
- –
- Price to sales
- 24.44
- Price to book
- 5.10
- Dividend yield
- –
- Free cash flow yield
- -8.12%
Fundamentals
- Revenue
- $104.97M
- Net income
- -$163.33M
- EPS, diluted
- -$2.17
- Free cash flow
- -$208.29M
- Book value per share
- $6.63
- Diluted shares
- 76M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $35.40
- Open
- $35.30
- Day's range
- $34.23 – $35.69
- Volume
- 1,616,922
- Average volume (20 days)
- 1,798,931
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- 52-week range
- $10.38 – $40.60
- RSI (14 days)
- 58.2
- Volatility (1 year)
- 65.1%
- Relative volume
- 1.13×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | XNCR | S&P 500 | Difference | XNCR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +51.0% | -4.0% | +55.0 pts | ||
| 3 months | +49.2% | -5.0% | +54.2 pts | ||
| Year to date | +125.3% | +8.2% | +117.1 pts | ||
| 1 year | +120.9% | +11.2% | +109.7 pts | ||
| 3 years | +79.5% | +68.5% | +11.0 pts | +21.5% | +19.0% |
| 5 years | -7.6% | +67.3% | −74.8 pts | -1.6% | +10.8% |
| 10 years | +28.8% | +291.6% | −262.8 pts | +2.6% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Xencor filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Xencor
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical firm focused on discovering and developing engineered antibody therapeutics for patients with cancer and autoimmune diseases. It leverages proprietary protein engineering technologies to design modular Fc domains and multi-specific antibody formats under the XmAb platform, which feature improved half-life, cytotoxic activity, and targeted immune mechanisms. Its pipeline includes wholly owned clinical-stage candidates such as XmAb819 and XmAb541 for oncology indications, and XmAb942, plamotamab, and XmAb657 for autoimmune and inflammatory conditions. The company targets patients with serious unmet medical needs and serves commercial biopharmaceutical partners through collaborative research, product licensing, and platform technology access agreements.
Company profile, executives and historyXencor stock: common questions
What is Xencor's stock price?
XNCR closed at $34.50 on Nov 17, 2026, down 2.54% on the day. Over the past 52 weeks it traded between $10.38 and $40.60.
What is Xencor's market cap?
Xencor was worth $2.57B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is XNCR's P/E ratio?
Xencor lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.17), so it has no meaningful P/E ratio.
How much revenue does Xencor make?
Xencor reported revenue of $104.97M for the twelve months to Jun 30, 2026, down 28.6% from a year earlier.
Does Xencor pay a dividend?
No. Xencor has not paid a cash dividend over the last twelve months.
When does Xencor report earnings next?
Xencor is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has XNCR stock performed over the past year?
Including dividends, XNCR returned +120.9% over the past year, against +11.2% for the S&P 500.
How many XNCR shares are sold short?
13M shares were sold short at the latest FINRA report, 17.62% of the float, or 6.6 days of average trading volume.
Who are Xencor's competitors?
Companies most similar to Xencor by business, industry and size include ZYME, MGNX, ANAB, PGEN, RCUS.
See a number that looks wrong?